Quantitative Systems Pharmacology: A Case for Disease Models

被引：48
|
作者：
Musante, C. J. [1 ]
Ramanujan, S. [2 ]
Schmidt, B. J. [3 ]
Ghobrial, O. G.
Lu, J. [4 ]
Heatherington, A. C. [1 ]
机构：
[1] Pfizer Inc, Cambridge, MA 02139 USA
[2] Genentech Inc, San Francisco, CA USA
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] AstraZeneca, Cambridge, England
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 101卷 / 01期
关键词：
PHARMACEUTICAL-INDUSTRY; MONOCLONAL-ANTIBODIES; DRUG DEVELOPMENT; THERAPEUTICS; CHALLENGES; INNOVATION; DISCOVERY;
D O I：
10.1002/cpt.528
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Quantitative systems pharmacology (QSP) has emerged as an innovative approach in model-informed drug discovery and development, supporting program decisions from exploratory research through late-stage clinical trials. In this commentary, we discuss the unique value of disease-scale "platform" QSP models that are amenable to reuse and repurposing to support diverse clinical decisions in ways distinct from other pharmacometrics strategies.
引用
收藏
页码：24 / 27
页数：4
相关论文
共 50 条
  • [41] Concepts and Challenges in Quantitative Pharmacology and Model-Based Drug Development
    Liping Zhang
    Marc Pfister
    Bernd Meibohm
    The AAPS Journal, 2008, 10 : 552 - 559
  • [42] Concepts and Challenges in Quantitative Pharmacology and Model-Based Drug Development
    Zhang, Liping
    Pfister, Marc
    Meibohm, Bernd
    AAPS JOURNAL, 2008, 10 (04): : 552 - 559
  • [43] Implications of Immunogenicity Testing for Therapeutic Monoclonal Antibodies: A Quantitative Pharmacology Framework
    Williams, Jason H.
    Liao, Kai H.
    Yin, Donghua
    Meng, Xu
    AAPS JOURNAL, 2024, 26 (02):
  • [44] Systems pharmacology to predict drug safety in drug development
    Trame, Mirjam N.
    Biliouris, Konstantinos
    Lesko, Lawrence J.
    Mettetal, Jerome T.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 94 : 93 - 95
  • [45] Business models design space for electricity storage systems: Case study of the Netherlands
    Kooshknow, S. A. R. Mir Mohammadi
    Davis, C. B.
    JOURNAL OF ENERGY STORAGE, 2018, 20 : 590 - 604
  • [46] Deciphering the multicomponent synergy mechanism from a systems pharmacology perspective: Application to Gualou Xiebai Decoction for coronary heart disease
    Yang, Yang
    Huang, Chao
    Su, Xing
    Zhu, Jinglin
    Chen, Xuetong
    Fu, Yingxue
    Wang, Zhenzhong
    Zhou, Jun
    Xiao, Wei
    Zheng, Chunli
    Wang, Yonghua
    JOURNAL OF FUNCTIONAL FOODS, 2018, 47 : 143 - 155
  • [47] Using quantitative systems pharmacology modeling to optimize combination therapy of anti-PD-L1 checkpoint inhibitor and T cell engager
    Anbari, Samira
    Wang, Hanwen
    Zhang, Yu
    Wang, Jun
    Pilvankar, Minu
    Nickaeen, Masoud
    Hansel, Steven
    Popel, Aleksander S. S.
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [48] High dimensionality reduction by matrix factorization for systems pharmacology
    Mehrpooya, Adel
    Saberi-Movahed, Farid
    Azizizadeh, Najmeh
    Rezaei-Ravari, Mohammad
    Saberi-Movahed, Farshad
    Eftekhari, Mahdi
    Tavassoly, Iman
    BRIEFINGS IN BIOINFORMATICS, 2022, 23 (01)
  • [49] Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection
    Sadekar, S.
    Figueroa, I.
    Tabrizi, M.
    AAPS JOURNAL, 2015, 17 (04): : 828 - 836
  • [50] Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal period
    Samardzic, Janko
    Allegaert, Karel
    Wilbaux, Melanie
    Pfister, Marc
    van den Anker, John N.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (04) : 367 - 375
12345